PRX Related Analyst EPS Change

Jul 20, 2012 08:31 AM Needham & Company maintains a 'Strong Buy' on Mylan (MYL); PRX Grossly Undervalued by TGP, MYL/PRX Instead As Strong Combo

May 31, 2012 02:11 PM Barclays Cuts Estimates on Par Pharmaceutical (PRX); Removing Lovaza Contribution From Model

May 9, 2012 12:21 PM UBS Maintains a 'Buy' on Par Pharmaceutical (PRX); Comments From Conference Call

May 9, 2012 08:14 AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Generic Core Delivers; Substantial Upside with Lovaza on Horizon

Apr 9, 2012 02:10 PM Barclays on U.S. Specialty Pharmaceuticals: Model Adjustments on MYL, PRX, TEVA, & WCRX